Arbutus Biopharma Files Definitive Proxy Statement

Ticker: ABUS · Form: DEF 14A · Filed: 2025-04-04T00:00:00.000Z

Sentiment: neutral

Topics: proxy-statement, annual-meeting, governance

Related Tickers: ABUS

TL;DR

Arbutus Biopharma (ABUS) filed its proxy statement for the May 21st meeting. Vote your shares!

AI Summary

Arbutus Biopharma Corp filed a Definitive Proxy Statement (DEF 14A) on April 4, 2025, for its annual meeting on May 21, 2025. The filing concerns the solicitation of proxies from shareholders regarding matters to be voted on at the meeting. Arbutus Biopharma, previously known as Tekmira Pharmaceuticals Corp, is in the pharmaceutical preparations industry.

Why It Matters

This filing provides shareholders with crucial information about the upcoming annual meeting, including proposals to be voted on, which can impact the company's governance and strategic direction.

Risk Assessment

Risk Level: low — This is a routine proxy filing for an annual meeting and does not contain new material financial or operational information that would inherently increase risk.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this DEF 14A filing?

The purpose of this DEF 14A filing is to provide shareholders with information and solicit their proxies for the upcoming annual meeting of shareholders scheduled for May 21, 2025.

When was this proxy statement filed with the SEC?

This proxy statement was filed with the SEC on April 4, 2025.

What is the company's Central Index Key (CIK)?

The company's Central Index Key (CIK) is 0001447028.

What was Arbutus Biopharma's former name?

Arbutus Biopharma Corporation was formerly known as Tekmira Pharmaceuticals Corp.

What is the company's primary business classification?

The company is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.

From the Filing

0001140361-25-012305.txt : 20250404 0001140361-25-012305.hdr.sgml : 20250404 20250404160540 ACCESSION NUMBER: 0001140361-25-012305 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20250521 FILED AS OF DATE: 20250404 DATE AS OF CHANGE: 20250404 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 25813987 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 DEF 14A 1 ny20041152x1_def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934         Filed by the Registrant ☒     Filed by a Party other than the Registrant   ☐         Check the appropriate box:   ☐ Preliminary Proxy Statement   ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement   ☐ Definitive Additional Materials   ☐ Soliciting Material under §240.14a-12   ARBUTUS BIOPHARMA CORPORATION (Name of Registrant as Specified in its Charter)   (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)   Payment of Filing Fee (Check all boxes that apply): ☒ No fee required   ☐ Fee paid previously with preliminary materials   ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 TABLE OF CONTENTS ARBUTUS BIOPHARMA CORPORATION 701 Veterans Circle Warminster, Pennsylvania 18974, United States (267) 469-0914 April 4, 2025 Dear Shareholder: You are cordially invited to attend Arbutus Biopharma Corporation’s 2025 Annual General Meeting of Shareholders to be held on Wednesday, May 21, 2025 (the “Annual Meeting”). The Annual Meeting will begin at 10:00 a.m. (Eastern Daylight Time) and will be held solely by means of live audio webcast online at http://www.virtualshareholdermeeting.com/ABUS2025. The enclosed Notice and Management Proxy Circular and Proxy Statement describe the matters to be presented at the Annual Meeting. Whether or not you plan to virtually attend the Annual Meeting, please vote as soon as possible to ensure that your shares will be represented and voted at the Annual Meeting. Due to voting rules that may prevent your bank or broker from voting your uninstructed shares on a discretionary basis in the election of directors and other non-routine matters, it is important that you cast your vote. We look forward to seeing you at the Annual Meeting.               Sincerely,                       Lindsay Androski, JD, MBA, CFA       Chairperson of the Board of Directors                 IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD VIRTUALLY VIA THE INTERNET ON MAY 21, 2025:       The Company is making this Proxy Statement/Circular, a form of proxy card, and our Annual Report for the year ended December 31, 2024 available electronically via the Internet at ww

View on Read The Filing